BusinessAmerican Journal of Psychiatry Publishes Minerva Neurosciences’ MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in SchizophreniaBy Nasdaq OMXJul 31, 2017, 12:30 PM UTC